146 related articles for article (PubMed ID: 22552285)
1. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells.
Nishizawa S; Hirohashi Y; Torigoe T; Takahashi A; Tamura Y; Mori T; Kanaseki T; Kamiguchi K; Asanuma H; Morita R; Sokolovskaya A; Matsuzaki J; Yamada R; Fujii R; Kampinga HH; Kondo T; Hasegawa T; Hara I; Sato N
Cancer Res; 2012 Jun; 72(11):2844-54. PubMed ID: 22552285
[TBL] [Abstract][Full Text] [Related]
2. Dnajb8, a Member of the Heat Shock Protein 40 Family Has a Role in the Tumor Initiation and Resistance to Docetaxel but Is Dispensable for Stress Response.
Yamashita M; Hirohashi Y; Torigoe T; Kusumoto H; Murai A; Imagawa T; Sato N
PLoS One; 2016; 11(1):e0146501. PubMed ID: 26751205
[TBL] [Abstract][Full Text] [Related]
3. Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells.
Morita R; Nishizawa S; Torigoe T; Takahashi A; Tamura Y; Tsukahara T; Kanaseki T; Sokolovskaya A; Kochin V; Kondo T; Hashino S; Asaka M; Hara I; Hirohashi Y; Sato N
Cancer Sci; 2014 Apr; 105(4):389-95. PubMed ID: 24450541
[TBL] [Abstract][Full Text] [Related]
4. Development of an artificial antibody specific for HLA/peptide complex derived from cancer stem-like cell/cancer-initiating cell antigen DNAJB8.
Tadano H; Tsukahara T; Mizushima E; Akamatsu A; Watanabe K; Nojima I; Kubo T; Kanaseki T; Hirohashi Y; Sato N; Torigoe T
Br J Cancer; 2020 Oct; 123(9):1387-1394. PubMed ID: 32753678
[TBL] [Abstract][Full Text] [Related]
5. Identification of antigenic peptides from novel renal cancer stem-like cell antigen, DNAJB8.
Nishizawa S; Hirohashi Y; Kusumoto H; Wakamiya T; Iguchi T; Yamashita S; Iba A; Kikkawa K; Kohjimoto Y; Torigoe T; Hara I
Biochem Biophys Res Commun; 2017 Dec; 494(3-4):693-699. PubMed ID: 29107688
[TBL] [Abstract][Full Text] [Related]
6. Cellular stress induces cancer stem-like cells through expression of DNAJB8 by activation of heat shock factor 1.
Kusumoto H; Hirohashi Y; Nishizawa S; Yamashita M; Yasuda K; Murai A; Takaya A; Mori T; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Kondo T; Sato N; Hara I; Torigoe T
Cancer Sci; 2018 Mar; 109(3):741-750. PubMed ID: 29316077
[TBL] [Abstract][Full Text] [Related]
7. Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours.
Watanabe Y; Tsukahara T; Murata K; Hamada S; Kubo T; Kanaseki T; Hirohashi Y; Emori M; Teramoto A; Nakatsugawa M; Yamashita T; Torigoe T
Br J Cancer; 2023 Mar; 128(5):886-895. PubMed ID: 36526673
[TBL] [Abstract][Full Text] [Related]
8. Preferential expression of cancer/testis genes in cancer stem-like cells: proposal of a novel sub-category, cancer/testis/stem gene.
Yamada R; Takahashi A; Torigoe T; Morita R; Tamura Y; Tsukahara T; Kanaseki T; Kubo T; Watarai K; Kondo T; Hirohashi Y; Sato N
Tissue Antigens; 2013 Jun; 81(6):428-34. PubMed ID: 23574628
[TBL] [Abstract][Full Text] [Related]
9. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme.
Broadley KW; Hunn MK; Farrand KJ; Price KM; Grasso C; Miller RJ; Hermans IF; McConnell MJ
Stem Cells; 2011 Mar; 29(3):452-61. PubMed ID: 21425408
[TBL] [Abstract][Full Text] [Related]
10. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
11. Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma.
Kano M; Tsukahara T; Emori M; Murase M; Torigoe T; Kawaguchi S; Wada T; Yamashita T; Sato N
Cancer Sci; 2011 Aug; 102(8):1443-7. PubMed ID: 21518139
[TBL] [Abstract][Full Text] [Related]
12. Efficiency of G2/M-related tumor-associated antigen-targeting cancer immunotherapy depends on antigen expression in the cancer stem-like population.
Mori T; Nishizawa S; Hirohashi Y; Torigoe T; Tamura Y; Takahashi A; Kochin V; Fujii R; Kondo T; Greene MI; Hara I; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):27-32. PubMed ID: 22001602
[TBL] [Abstract][Full Text] [Related]
13. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
14. Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells.
Hirohashi Y; Torigoe T; Inoda S; Takahashi A; Morita R; Nishizawa S; Tamura Y; Suzuki H; Toyota M; Sato N
Immunotherapy; 2010 Mar; 2(2):201-11. PubMed ID: 20635928
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma.
Ogushi T; Takahashi S; Takeuchi T; Urano T; Horie-Inoue K; Kumagai J; Kitamura T; Ouchi Y; Muramatsu M; Inoue S
Cancer Res; 2005 May; 65(9):3700-6. PubMed ID: 15867365
[TBL] [Abstract][Full Text] [Related]
16. Cancer stem cell niche: the place to be.
Borovski T; De Sousa E Melo F; Vermeulen L; Medema JP
Cancer Res; 2011 Feb; 71(3):634-9. PubMed ID: 21266356
[TBL] [Abstract][Full Text] [Related]
17. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
[TBL] [Abstract][Full Text] [Related]
18. RBP2 induces stem-like cancer cells by promoting EMT and is a prognostic marker for renal cell carcinoma.
Zhou D; Kannappan V; Chen X; Li J; Leng X; Zhang J; Xuan S
Exp Mol Med; 2016 Jun; 48(6):e238. PubMed ID: 27282106
[TBL] [Abstract][Full Text] [Related]
19. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma.
Gaudin C; Kremer F; Angevin E; Scott V; Triebel F
J Immunol; 1999 Feb; 162(3):1730-8. PubMed ID: 9973436
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110.
Kim HL; Sun X; Subjeck JR; Wang XY
Cancer Immunol Immunother; 2007 Jul; 56(7):1097-105. PubMed ID: 17146628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
